Randi Hagerman is a distinguished professor of pediatrics and the medical director of the Medical Investigation of Neurodevelopmental Disorders (MIND) Institute at the University of California, Davis School of Medicine. She holds an Endowed Chair in Fragile X Research and has over 35 years of experience in working with those with fragile X syndrome, autism and premutation disorders.

Hagerman directs the clinical trials unit at the MIND Institute and has carried out numerous studies of targeted treatments in neurodevelopmental conditions. She also directs the Fragile X Treatment and Research Center at the MIND Institute and follows many families with both premutations and full mutations in FMR1.

Hagerman co-founded the National Fragile X Foundation (NFXF) in 1984 and serves on their Scientific and Clinical Advisory Committee as well as their Clinical Trials Committee. She is also an emeritus member of NFXF’s board of directors.